News

Filter

Current filters:

bapineuzumabResearch

J&J and Pfizer drop bapineuzumab development for Alzheimer's

07-08-2012

There was disappointing - though not really unexpected - news yesterday for US health care giant Johnson…

bapineuzumabElanJanssenJohnson & JohnsonNeurologicalPfizerPharmaceuticalResearch

Pfizer and Janssen's bapineuzumab fails to meet one Ph III study endpoints for Alzheimer's

24-07-2012

US drugs behemoth Pfizer (NYSE: PFE) revealed yesterday that the co-primary clinical endpoints, change…

bapineuzumabJanssenJohnson & JohnsonNeurologicalPfizerPharmaceuticalResearch

COMPANY SPOTLIGHT

Menarini

Back to top